Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COCPNASDAQ:ERNANYSE:NKGNNASDAQ:RWOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOCPCocrystal Pharma$1.46$1.44$1.12▼$3.26$14.85M2.1328,462 shs13,448 shsERNAEterna Therapeutics$0.23-0.2%$0.21$0.15▼$2.63$14.22M5.612.80 million shs444,010 shsNKGNNKGen Biotech$0.29+11.5%$0.18$0.10▼$1.87$13.03M0.841.57 million shs52,405 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOCPCocrystal Pharma0.00%+2.82%+3.55%-25.13%-29.13%ERNAEterna Therapeutics-0.18%+1.79%+17.65%-27.60%-88.54%NKGNNKGen Biotech+11.46%-17.15%+136.57%-49.11%-83.72%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-87.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOCPCocrystal Pharma3.2177 of 5 stars3.55.00.00.03.31.70.6ERNAEterna Therapeutics0.7629 of 5 stars0.05.00.00.00.01.70.6NKGNNKGen BiotechN/AN/AN/AN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOCPCocrystal Pharma 3.00Buy$7.00379.45% UpsideERNAEterna Therapeutics 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ARWODRedwoods Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOCPCocrystal PharmaN/AN/AN/AN/A$2.59 per shareN/AERNAEterna Therapeutics$535K26.58N/AN/A$0.41 per share0.56NKGNNKGen Biotech$80K162.82N/AN/A($2.68) per share-0.11RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOCPCocrystal Pharma-$17.98M-$1.57N/AN/AN/AN/A-94.62%-78.24%N/AERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/ARWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RWOD, NKGN, COCP, and ERNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025COCPCocrystal Pharma-$0.52-$0.23+$0.29-$0.23N/AN/A3/27/2025Q4 2024COCPCocrystal Pharma-$0.55-$0.32+$0.23-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOCPCocrystal PharmaN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOCPCocrystal PharmaN/A7.327.32ERNAEterna TherapeuticsN/A0.480.48NKGNNKGen BiotechN/A0.020.02RWODRedwoods AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOCPCocrystal Pharma6.72%ERNAEterna Therapeutics70.55%NKGNNKGen Biotech76.17%RWODRedwoods Acquisition20.07%Insider OwnershipCompanyInsider OwnershipCOCPCocrystal Pharma28.14%ERNAEterna Therapeutics4.49%NKGNNKGen Biotech10.36%RWODRedwoods Acquisition2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOCPCocrystal Pharma1010.17 million7.57 millionNot OptionableERNAEterna Therapeutics1062.36 million5.17 millionNo DataNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableRWOD, NKGN, COCP, and ERNA HeadlinesRecent News About These CompaniesCal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public OfferingMay 23 at 6:55 AM | bakersfield.comRedwood Holdings Limited vow to return Reading ‘to its rightful place in English football’ after completing takeoverMay 15, 2025 | nytimes.comRedwood Services Makes 19th AcquisitionMay 15, 2025 | achrnews.comRedwood Announces Investment by Atlas PartnersMay 9, 2025 | achrnews.comRedwood Materials preps for expansion spree with new R&D center in San FranciscoApril 2, 2025 | msn.comBlank-Check Company Cal Redwood Files for IPOMarch 4, 2025 | marketwatch.comEnvironmental Groups Praise Plan to Conserve Coastal Redwoods, Expand Protected LandFebruary 20, 2025 | sanjoseinside.com$24 million land deal creates 7-mile-long Bay Area corridor of protected redwood forests to the oceanFebruary 12, 2025 | msn.comSave the Redwoods League signs $24 million deal to purchase Monte Rio redwood forest and expand county parkFebruary 12, 2025 | pressdemocrat.com$24 million land deal creates 7-mile long corridor of protected redwood forests to the oceanFebruary 11, 2025 | eastbaytimes.comRedwood Gospel Mission finalizes purchase of former SAY Dream Center in Santa RosaJanuary 5, 2025 | pressdemocrat.comRedwood Empire Whiskey Acquires Luxury Northern California DistilleryDecember 21, 2024 | markets.businessinsider.comAcacia Capital buys Redwood City apartments for $184MNovember 13, 2024 | therealdeal.comRedwood Realty Negotiates $6.6M Sale of Jersey City Apartment BuildingOctober 24, 2024 | rebusinessonline.comSave the Redwoods League acquires 750 acres of Redwood Forest in Sonoma and Mendocino Counties for future parks expansionsOctober 13, 2024 | ukiahdailyjournal.comOne of California's most popular old-growth redwood parks is about to get biggerOctober 11, 2024 | msn.comSave the Redwood League acquires 750 acres of land to expand Montgomery Woods, Armstrong WoodsOctober 11, 2024 | mendovoice.comRedwood Gospel Mission in line to buy former SAY Dream Center campus in Santa RosaOctober 6, 2024 | pressdemocrat.comBMW of North America partners with Redwood MaterialsSeptember 27, 2024 | recyclingtoday.comThree miles of scenic Northern California coastline preserved in major redwoods dealSeptember 12, 2024 | times-standard.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRWOD, NKGN, COCP, and ERNA Company DescriptionsCocrystal Pharma NASDAQ:COCP$1.46 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.43 -0.03 (-2.05%) As of 05/23/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.Eterna Therapeutics NASDAQ:ERNA$0.23 0.00 (-0.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.23 0.00 (0.00%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.NKGen Biotech NYSE:NKGN$0.29 +0.03 (+11.46%) As of 05/23/2025 03:55 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
